Peyman Gholam A, Tsipursky Michael, Nassiri Nariman, Conway Mandi
Department of Ophthalmology, Tulane University, New Orleans, Louisiana, USA.
J Ophthalmic Vis Res. 2011 Jul;6(3):166-76.
To report the preliminary results of oscillatory photodynamic therapy (OPDT) for choroidal neovascularization (CNV) and central serous retinopathy (CSR).
This study included 7 eyes of 6 patients with CSR (2 eyes), idiopathic CNV (2 eyes), CNV due to age-related macular degeneration (AMD) (2 eyes), and peripapillary CNV secondary to presumed ocular histoplasmosis syndrome (1 eye). Intravenous verteporfin (6 mg/m(2) body surface area) was infused over 10 minutes followed by oscillating laser (wavelength 689 nm) covering slightly beyond the entire lesion. An Area Centralis lens was applied and laser was delivered (600 mW/cm(2) fluence rate and 50 J/cm(2) dose). Intravitreal bevacizumab and dexamethasone combination therapy was used with OPDT in 4 eyes with CNV; intravitreal dexamethasone and triamcinolone acetonide were injected in the other eye with CNV. Clinical examination, funduscopy, fluorescein angiography, and optical coherence tomography (OCT) were performed at baseline and after treatment.
After mean follow-up of 7.1±5.1 months, visual acuity improved from 0.87±0.69 logMAR (20/160) to 0.60±0.65 logMAR (20/80) (P = 0.027); central foveal thickness decreased from 322±62.1 to 240.7±34.8 microns as measured by OCT (P = 0.018). Fluorescein angiography and OCT demonstrated cessation of vascular leakage, and resolution of hemorrhage and subretinal fluid in all eyes. No adverse events or recurrence were noted.
OPDT was effective in treating CNV lesions and CSR. OPDT may be an improvement on standard PDT due to reduced side effects, thermal damage and scarring.
报告振荡光动力疗法(OPDT)治疗脉络膜新生血管(CNV)和中心性浆液性视网膜病变(CSR)的初步结果。
本研究纳入6例患者的7只眼,其中CSR患者2只眼、特发性CNV患者2只眼、年龄相关性黄斑变性(AMD)所致CNV患者2只眼、疑似眼组织胞浆菌病综合征继发的视乳头周围CNV患者1只眼。静脉注射维替泊芬(6mg/m²体表面积),持续10分钟,随后用振荡激光(波长689nm)覆盖整个病变区域并稍超出其范围。使用中央凹透镜,给予激光(能量密度600mW/cm²,剂量50J/cm²)。4只患有CNV的眼睛在接受OPDT治疗时联合玻璃体内注射贝伐单抗和地塞米松;另一只患有CNV的眼睛则注射玻璃体内地塞米松和曲安奈德。在基线和治疗后进行临床检查、眼底检查、荧光素血管造影和光学相干断层扫描(OCT)。
平均随访7.1±5.1个月后,视力从0.87±0.69 logMAR(20/160)提高到0.60±0.65 logMAR(20/80)(P = 0.027);经OCT测量,中心凹厚度从322±62.1微米降至240.7±34.8微米(P = 0.018)。荧光素血管造影和OCT显示所有眼睛的血管渗漏停止,出血和视网膜下液消退。未观察到不良事件或复发情况。
OPDT治疗CNV病变和CSR有效。由于副作用、热损伤和瘢痕形成减少,OPDT可能是对标准光动力疗法的一种改进。